Akorn adds Doxercalciferol Injection Solution in single-use vials to product line
An abbreviated new drug application for the product was approved by the U.S. Food and Drug Administration on May 7.
The new product is therapeutically equivalent to Hectorol injection, marketed by Genzyme Corp. Doxercalciferol Injection is used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis.
Branded and generic sales of Doxercalciferol Injection in single-use vials were approximately $90 million for the 12-month period that ended July 31.
Akorn develops, manufactures and markets multisource and branded pharmaceuticals. Akorn operates manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland; and Paonta Sahib, India.